<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04192916</url>
  </required_header>
  <id_info>
    <org_study_id>MPN-DOACs</org_study_id>
    <nct_id>NCT04192916</nct_id>
  </id_info>
  <brief_title>Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms</brief_title>
  <acronym>MPN-DOACs</acronym>
  <official_title>Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione per la Ricerca Ospedale Maggiore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione per la Ricerca Ospedale Maggiore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with myeloproliferative neoplasms (MPN) are predisposed to have an increased
      thrombotic and hemorrhagic risk and, in this context, the use of newly approved direct oral
      anticoagulants (DOACs) may have improved bleeding risk compared to warfarin use. However, the
      published experience is very limited and does not allow any conclusion. In the cohort of
      patients with MPN and venous thromboembolism (VTE) of European Leukemia-net, only 3.3% of
      patients had been treated with DOACs. Similarly, in a recent publication of a series of 760
      patients with single-center MPN, only 25 (3.3%) were treated with a DOAC (13 for atrial
      fibrillation and 12 for thrombotic events).

      While it is known that the risk of thrombotic recurrence and haemorrhagic event during
      warfarin treatment is about 30% at 5 years from the first event, the actual risk of such
      events in MPN patients is not known.

      The aim of the present study is therefore to obtain information on patients with MPN treated
      with DOAC for atrial fibrillation (AF) and VTE. This is an international multi-center
      retrospective survey aimed at describing the efficacy / safety of DOAC in the prevention of:

        -  cardioembolic stroke in patients with MPN with AF

        -  recurrent thrombosis in patients with MPN with VTE

        -  major bleeding in all patients with MPN.

      The results will allow to design future prospective studies that evaluate the benefit / risk
      profile of DOAC compared to warfarin in these pathologies characterized by high risk of
      thrombosis and, in some subgroups, of bleeding.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Combined risk of major thrombosis and bleeding</measure>
    <time_frame>At 5 year from the start of treatment with DOACs</time_frame>
    <description>cardioembolic strokes in MPN patients with Atrial fibrillation OR
recurrent thrombosis in MPN patients with Venous Thromboembolism OR
major bleeding in all MPN patients</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Myeloproliferative Neoplasm</condition>
  <arm_group>
    <arm_group_label>MPN patients treated with DOACs</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOACs</intervention_name>
    <description>Direct Oral Anticoagulants</description>
    <arm_group_label>MPN patients treated with DOACs</arm_group_label>
    <other_name>Dabigatran</other_name>
    <other_name>Edoxaban</other_name>
    <other_name>Rivaroxaban</other_name>
    <other_name>Apixaban</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with MPN treated with any DOAC for AF or VTE
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of Philadelphia-negative MPN according to World Health Organization (WHO)
             2008 and/or 2016 criteria until 31/12/2018;

          -  diagnosis of atrial fibrillation (AF) and/or diagnosis of venous thromboembolism (VTE)
             including thrombosis of deep veins of the limbs and the abdomen, cerebral and
             splanchnic veins (hepatic, portal, mesenteric, and splenic veins) and pulmonary
             embolism;

          -  treatment with DOACs.

        Exclusion Criteria:

        â€¢ Administration of DOAC for any medical reason other than AF and/or VTE (excluding
        superficial vein thrombosis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alessandra Carobbio</last_name>
    <phone>+390352675136</phone>
    <email>acarobbio@fondazionefrom.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mount Sinai New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Mascarenhas</last_name>
      <email>john.mascarenhas@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>John Mascarenhas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre Toronto</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hassan Sibai</last_name>
      <email>Hassan.Sibai@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Hassan Sibai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Christophe Ianotto</last_name>
      <email>jean-christophe.ianotto@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Christophe Ianotto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RWTH Aachen University</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>kim Kricheldorf</last_name>
      <email>kkricheldorf@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Steffen Koschmieder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Wille</last_name>
      <email>kai.wille@muehlenkreiskliniken.de</email>
    </contact>
    <investigator>
      <last_name>Martin Grieshammer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione Ematologia, Ospedale Borgo Roma</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Rossi</last_name>
      <phone>0458126564</phone>
      <email>irene.rossi@crc.vr.it</email>
    </contact>
    <investigator>
      <last_name>Massimiliano Bonifacio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luigi Scaffidi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST- Papa Giovanni XXIII - S.I.M.T.</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Falanga, MD</last_name>
      <email>afalanga@asst-pg23.it</email>
    </contact>
    <investigator>
      <last_name>Anna Falanga, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesca Palandri</last_name>
      <email>francesca.palandri@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Francesca Palandri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Careggi di Firenze</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chiara Paoli</last_name>
      <email>chiara.paoli@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro M Vannucchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paola Guglielmelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST MONZA Ospedale San Gerardo Clinica Ematologica</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Elli, Dr</last_name>
      <email>elena.elli@libero.it</email>
    </contact>
    <investigator>
      <last_name>Elena Elli, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II di Napoli Divisione di Ematologia e Trapianti del Midollo</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Monteverde</last_name>
      <email>mariamonteverde1@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fabrizio Pane, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Novella Pugliese, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico di Palermo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Santoro</last_name>
      <email>santoro.dott@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sergio Siragusa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo S.C Ematologia</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chiara Cavalloni</last_name>
      <email>chiara.cavalloni@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elisa Rumi, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli IRCCS UCSC Ematologia</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Soldati</last_name>
      <email>denise.soldati@unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Valerio De Stefano, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Rossi, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Betti, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. CittÃ  della Salute e della Scienza di Torino - Ospedale Molinette- S.C. Ematologia</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesca Pirillo</last_name>
      <email>fpirillo@cittadellasalute.to.it</email>
    </contact>
    <investigator>
      <last_name>Giulia Benevolo, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo di Vicenza - U.O.C di Ematologia</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Carli, Dr</last_name>
      <email>g.carli@aulss8.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Carli, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic, Hematology Department</name>
      <address>
        <city>Barcellona</city>
        <zip>08034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Alvarez Larran, Dr</last_name>
      <email>aalvar@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Alberto Alvarez Larran, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Cervantes, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire Harrison, Prof</last_name>
    </contact>
    <contact_backup>
      <email>claire.harrison@gstt.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Claire Harrison, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clemency Stephenson, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Efficacy and safety profile</keyword>
  <keyword>Direct oral anticoagulants</keyword>
  <keyword>Real world data</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

